# An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

> **NCT05532020** · PHASE2 · UNKNOWN · sponsor: **Soleno Therapeutics, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- SH2B1 Deficiency Obesity
- Obesity Associated With PCSK1 Mutation (rs6232 Variant)
- SIM1 Deficiency Obesity

## Interventions

- **DRUG:** DCCR (diazoxide choline) extended-release tablets

## Key facts

- **NCT ID:** NCT05532020
- **Lead sponsor:** Soleno Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532020, "An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05532020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*